The generic segment forms a critical part of the U.S. pharmaceutical industry, offering cost-effective alternatives to branded drugs once their patents expire. Generics are bioequivalent to branded products in efficacy and safety, making them a preferred choice for healthcare providers, payers, and patients seeking affordable treatment options. This segment is driven by several key factors, including increasing patent expirations, rising healthcare cost pressures, and supportive regulatory frameworks that streamline generic drug approvals. However, Patent expiration of key pharmaceutical drugs has emerged as a significant restraint for the growth of the U.S. pharmaceutical industry. Once patents expire, generic versions of these drugs can enter the market, often leading to a sharp decline in sales for the original branded drugs. For instance, in January 2023, the patent for AbbVie’s blockbuster drug Humira (adalimumab), which generated over USD 20 billion in annual sales, expired, allowing biosimilars to compete.
This breakthrough has reshaped the obesity treatment paradigm for both patients and providers, offering a viable medical solution to a condition long viewed as difficult to manage. Coupled with advances in digital health tools, these therapies are part of integrated care models that combine pharmacological treatments with technology, behavioral coaching, and personalized interventions. This comprehensive approach not only addresses obesity but also improves overall patient outcomes, presenting a credible pathway to overcoming a major public health challenge in the U.S. The starkly different operating environments across these key global markets underscore a critical strategic reality. The historical model of developing a generic drug and launching it with a largely uniform global strategy is no longer viable. The policy-driven market of China’s VBP requires a focus on cost and scale that is fundamentally different from the needs of the U.S. market, where navigating patent law and the IRA’s pricing provisions is paramount.
Prescription Drugs Market Scope
- A sophisticated literature exists to explore the supply and demand sides of these markets for addictive legal products.
- They offer cost savings for patients and healthcare systems, drive market competition and innovation, and contribute to the sustainability of healthcare systems.
- The growing aging population and increasing cancer incidence among them and advancements in cancer treatments are fostering segment growth.
- The generic segment is expected to register the fastest growth rate over the projected period, driven by a high number of patent expiries in 2024, increasing demand for affordable medications, and rising healthcare expenditure.
- Hospital pharmacies dominate the distribution landscape, with retail pharmacies playing a growing role in chronic disease management.
- By therapeutic area, the immunology segment is expected to grow at the fastest CAGR in the projected period.
In terms of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies & drug stores, and online pharmacies. This group is the largest and consumes various pharmaceutical products for better health and to improve quality of life. There is a substantial noneconomic literature about the supply side of drug markets, particularly at the retail level. For New York City in particular, there is a long tradition of ethnographic studies of the subject (e.g., Johnson et al., 1985; Preble and Casey, 1969) that has produced rich descriptions of individual markets. For example, Bourgois spent 3 years in a Hispanic section of Harlem observing the activities and lives of a small group of dealers (Bourgois, 1996). A report of the National Research Council (2001) made extensive reference to work by Curtis and Wendel (2000).
Market Share Of Leading 10 National Pharmaceutical Markets Worldwide In 2024
Retail pharmacies offer several facilities, such as special discounts and same-day home delivery, augmenting the segment’s growth. When a drug loses its patent protection and exclusivity, it creates opportunities for generic drug manufacturers to enter the market and produce their versions of the drug. This promotes competition and helps drive down drug prices, making medications more affordable for patients. In addition, Off-patent, off-exclusivity drugs are typically priced lower than their brand-name counterparts. This cost advantage makes them more accessible to patients and contributes to significant cost savings for healthcare systems and insurance providers.
Medicare Part D Sees Largest Volume Growth Among Payment Methods
The approval of cutting-edge drugs such as CAR-T cell therapies for certain cancers exemplifies the market’s growing focus on precision medicine, offering hope for previously untreatable conditions. A notable advancement is the continued progression in immuno-oncology treatments, which are redefining cancer care. The global pharmaceutical market size was estimated at USD 1,645.75 billion in 2024 and is projected to reach USD 2,350.43 billion by 2030, growing at a CAGR of 6.12% from 2025 to 2030. The market is driven by rising chronic disease prevalence, aging populations, and increased healthcare spending.
Related Pharmaceuticals Reports
The leading companies are not standing still; they are actively reshaping their business models to adapt to the industry’s evolving pressures and opportunities. A “High-Cost Medical Expense Benefit” system caps patients’ monthly out-of-pocket payments. This impending cliff encompasses some of the world’s best-selling medicines, creating multi-billion-dollar opportunities in high-value therapeutic areas such as oncology, immunology, and cardiovascular disease. As shown in Table 2, major products like Merck’s cancer immunotherapy Keytruda, Johnson & Johnson’s immunology drug Stelara, and Bristol Myers Squibb’s anticoagulant Eliquis are all slated to face generic or biosimilar competition before the end of the decade.
US Pharmaceutical Market Outlook And Strategic Insights By 2030
By formulation, the sprays segment is expected to grow at the fastest rate during the forecast period. Sprays use atomization to transform a liquid or solid composition into a dynamic combination spread across a gas. The global pharmaceuticals market size was estimated at USD 1,645.75 billion in 2024 and is expected to reach USD 1,746.47 billion in 2025. Despite efforts to reduce drug consumption in the United States over the past 35 years, drugs are just as cheap and available as they have ever been.
For chronic conditions, lifestyle interventions and non-pharmacological therapies (e.g., behavioral programs or surgical options) can serve as substitutes. Additionally, the rise of biosimilars presents competition for biologics, particularly in therapeutic areas like oncology and immunology. Despite this, branded pharmaceuticals maintain a strong position due to innovation, brand loyalty, and superior efficacy in many cases. The global generic drug market is a fiercely competitive arena dominated by a handful of multinational titans, a dynamic cohort of specialized players, and a vast number of smaller regional manufacturers. Success in this environment requires not only operational excellence and scale but also sophisticated strategic planning, astute portfolio management, and a deep understanding of the intellectual property landscape.
US Pharmaceutical Market Trends
Also, this kind of consistent innovation impels demand for branded drugs, as patients are looking for novel treatments for different diseases. Patients prefer branded drugs because of their recognized quality, efficacy, or familiarity with the brand names. Leading companies in the pharmaceutical and drug development industries focus on developing and improving existing technologies to enhance patient outcomes and improve healthcare effectiveness. These efforts include advancing drug formulations, optimizing delivery methods, and expanding therapeutic applications.
However, once we narrowed the market to only specialty drugsand the highest priced drugs, then competition in both markets erodedsubstantially. Among specialty drugs, 63 percent of small molecule drugs and87 percent of biological products had only a single manufacturer. Finally,when examining only the highest priced drugs (i.e., those in the top 10percent of spending per prescription), we found that 11 percent of smallmolecule drugs and 0 percent of biological products had at least 2manufacturers. Figure 3 shows thelevel of competition among specialty drugs in small molecule drug andbiological product markets, and both curves show an increase in theshare of single-manufacturer products. In total, there were 347specialty small molecule drugs in 2017 (19 percent of all small moleculedrugs), which increased to 434 by 2022 (24 percent of all small moleculedrugs). In 2022, 273 specialty small molecule drugs (63 percent) hadonly one manufacturer, 51 specialty small molecule drugs had 2-3manufacturers (12 percent), and 26 specialty small molecule drugs (6percent) had 4-5 manufacturers.
Generic Drugs Market Size, Research, Trends And Forecast
The adults segment held the largest market share of 62.84% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. The adult population aged from years holds the largest share in the total population and are the major consumer of prescription medicine. According to CDC,in U.S., around 69.0% and in Canada, around 65.5%, accounting to nearly 7 in 10 persons aged used at least one prescription drug. The most commonly used drug among the adult population includes lipid-lowering drugs, ACE inhibitors, analgesics, and antidepressants. The rising awareness among the adult population regarding diseases and available medicine is further propelling demand for effective therapeutics subsequently fueling growth of overall U.S.
As well as this online access for medication, which is often with door-to-door delivery, is significantly driving market growth, especially for people with restricted mobility or those in rural areas. By therapeutic area, the oncology segment dominated by holding a major revenue share of the drugs market in 2024. Over the globe, the leading cause of death is cancer, which is prevalent and increases consistently due to factors such as, geriatric population, lifestyle changes, and environmental factors.
Also, the raised adoption of technological advancements like telehealth and remote patient tracking enables healthcare providers to monitor patients’ progress and supplies support from home, with affordable features as well. By therapeutic area, the immunology segment is expected to grow at the fastest CAGR in the projected period. Several factors are contributing, such as accelerating autoimmune cases like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease are majorly propelling the expansion of the drugs market. Although in the community, rising adoption of highly developed treatments like targeted therapies, approval of biologics are transforming the treatment approaches for immunological disorders.
By product type, the over-the-counter (OTC) drugs segment is expected to be the fastest CAGR growing in the upcoming years. Nowadays, consumers are widely adopting OTC drugs to resolve insignificant ailments and track their complete well-being, because of their convenience and reasonable compared to prescription drugs. Also, rising emphasis on proactive health management is resulting in a greater demand for OTC products, which is coupled with self-care and preventive measures. The worldwide drugs market is experiencing significant expansion, with projections indicating a revenue increase reaching several hundred million dollars by the end of the forecast period, spanning 2025 to 2034. The increasing prevalence of cardiovascular diseases, cancer, diabetes, and neurological disorders is fueling the demand for innovative treatments and personalized medicine. Companies also invest in artificial intelligence (AI), big data analytics, and real-world evidence (RWE) research to enhance drug discovery and market access.
Further developing the economic approach to capture more of the features of real-world drug markets across the world is an important on-going research topic. Table 4 showsdrug expenditures and total prescriptions for the top 10 percent ofdrugs based on price per prescription (“highest priceddrugs”) from 2017 to 2022. However,the number of prescriptions for the highest priced drugsdecreased from 13.2 million in 2017 to 11.4 millionin 2022, a 14 percent decrease. This means that spending perprescription among the highest priced drugs increased by 45 percent$6,561 in 2017 to $9,505 in 2022. Similar to the overall small molecule drug and biological productmarkets, we saw that in the specialty market, there was more competitionamong small molecule drugs than among biological products. We alsoobserved a greater percentage increase in biological products with asingle manufacturer over time, 44 percent, relative to a 19 percentincrease among small molecule drugs.
